Meeting
2018 ASCO Annual Meeting
Association of STK11/LKB1 mutations with primary resistance to PD-1/PD-L1 axis blockade in PD-L1 positive non-squamous NSCLC.
Authors
Ferdinandos Skoulidis
The University of Texas MD Anderson Cancer Center, Houston, TX
Ferdinandos Skoulidis , Brett W. Carter , Jianjun Zhang , Ignacio Ivan Wistuba , Vassiliki Papadimitrakopoulou , John Heymach
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Citation
J Clin Oncol 36, 2018 (suppl; abstr 9028)
DOI
10.1200/JCO.2018.36.15_suppl.9028
Abstract #
9028
Poster Bd #
351
Abstract Disclosures
Similar Posters
First Author: Jeddeo Paul
Poster
2019 ASCO Annual Meeting
Anti-PD-1/PD-L1 plus chemotherapy versus chemotherapy alone in first-line treatment for patients with metastatic NSCLC that were PD-L1 negative or less than 1 %.
First Author: Thierry Landre
Poster
2016 ASCO Annual Meeting
Evaluation of toxicity profile of PD-1 versus PD-L1 inhibitors in non-small cell lung cancer (NSCLC).
First Author: Rathi Narayana Pillai
Poster
2016 ASCO Annual Meeting
Meta-analysis of tumor PD-L1 expression as a predictive biomarker of benefit from PD-1/PD-L1 axis inhibitors in solid tumors.
First Author: Monica Khunger